Document type
ArticleVersion
Accepted versionPublication date
All rights reserved
Please use this identifier to cite or link to this item: https://hdl.handle.net/2445/67135
Carryover negligibility and relevance in bioequivalence studies
Journal Title
Director/Tutor
Journal ISSN
Volume Title
Related resource
Abstract
The carryover effect is a recurring issue in the pharmaceutical field. It may strongly influence the final outcome of an average bioequivalence study. Testing a null hypothesis of zero carryover is useless: not rejecting it does not guarantee the non-existence of carryover, and rejecting it is not informative of the true degree of carryover and its influence on the validity of the final outcome of the bioequivalence study. We propose a more consistent approach: even if some carryover is present, is it enough to seriously distort the study conclusions or is it negligible? This is the central aim of this paper, which focuses on average bioequivalence studies based on 2×2 crossover designs and on the main problem associated with carryover: type I error inflation. We propose an equivalence testing approach to these questions and suggest reasonable negligibility or relevance limits for carryover. Finally, we illustrate this approach on some real datasets.
Subject
Subject (English)
Citation
Citation
OCAÑA I REBULL, Jordi, SÁNCHEZ OLAVARRÍA, María Pilar and CARRASCO JORDAN, Josep Lluís. Carryover negligibility and relevance in bioequivalence studies. Pharmaceutical Statistics. 2015. Vol. 14, num. 5, pags. 400-408. ISSN 1539-1604. [consulted: 7 of August of 2026]. Available at: https://hdl.handle.net/2445/67135